Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20736297 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Zelivianski S, Cooley A, Kall R, Jeruss JS (2010) Cyclin-dependent kinase 4-mediated phosphorylation inhibits smad3 activity in cyclin d-overexpressing breast cancer cells. Mol Cancer Res 8, 1375-87 20736297
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T8-p - Smad3 (human)
Orthologous residues
Smad3 (human): T8‑p, Smad3 (mouse): T8‑p, Smad3 (rat): T8‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  Hs 578T (breast cell), MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
Downstream Regulation
 Effect of modification (process):  cell cycle regulation, transcription, inhibited
 Comments:  induces G1 blockade

T179-p - Smad3 (human)
Orthologous residues
Smad3 (human): T179‑p, Smad3 (mouse): T179‑p, Smad3 (rat): T179‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  Hs 578T (breast cell), MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
Downstream Regulation
 Effect of modification (process):  cell cycle regulation, transcription, inhibited
 Comments:  induces G1 blockade

S204-p - Smad3 (human)
Orthologous residues
Smad3 (human): S204‑p, Smad3 (mouse): S204‑p, Smad3 (rat): S204‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  Hs 578T (breast cell), MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
Downstream Regulation
 Effect of modification (process):  transcription, inhibited

S208-p - Smad3 (human)
Orthologous residues
Smad3 (human): S208‑p, Smad3 (mouse): S208‑p, Smad3 (rat): S208‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  Hs 578T (breast cell), MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
Downstream Regulation
 Effect of modification (process):  transcription, inhibited

S213-p - Smad3 (human)
Orthologous residues
Smad3 (human): S213‑p, Smad3 (mouse): S213‑p, Smad3 (rat): S213‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  Hs 578T (breast cell), MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) siRNA inhibition of enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
Downstream Regulation
 Effect of modification (process):  transcription, inhibited

S423-p - Smad3 (human)
Orthologous residues
Smad3 (human): S423‑p, Smad3 (mouse): S423‑p, Smad3 (rat): S423‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human

S425-p - Smad3 (human)
Orthologous residues
Smad3 (human): S425‑p, Smad3 (mouse): S425‑p, Smad3 (rat): S425‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  MCF-7 (breast cell), T47D (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.